在糖尿病黄斑瘤中Aflibercept的非目标效应:一种in-silico建模方法
Morgane Blanot1, Ricardo Pedro Casaroli-Marano2,3, Jordi Mondéjar-Medrano4
1Anaxomics Biotech S.L., 08007 Barcelona, Spain.
International journal of molecular sciences
|April 13, 2024
概括
内阿弗利塞普特注射 (IAI) 通过抑制VEGFR1和VEGFR2通路,有效治疗糖尿病黄斑胀 (DME). 这个计算机模拟显示了IAIAI.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 糖尿病黄斑 (DME) 是糖尿病患者视力丧失的主要原因.
- 内阿弗利塞普特注射 (IAI) 是对DME的标准治疗方法,但其精确的作用机制 (MoA) 需要进一步阐明.
- 了解IAI的多目标MOA对于优化DME治疗策略至关重要.
研究的目的:
- 探索IAI在糖尿病黄斑 (DME) 病理生理学的详细的MOA.
- 通过一种in silico疾病模型来研究IAI的多目标性质.
- 评估VEGFR1通路抑制在DME治疗中的特定作用.
主要方法:
- 利用治疗性能映射系统创建DME病理生理学的数学模型.
- 模拟了IAI对血管内皮生长因子受体 (VEGFR) 和DME相关过程的影响.
- 进行了丰富分析和可视化预测的蛋白质活性,以了解IAI的影响.
主要成果:
- 在模型模拟DME病理生理学和IAI的MoA通过VEGFR1和VEGFR2抑制.
- IAI显著调节了关键的DME过程,包括血管生成,血视网膜屏障完整性和炎症.
- 发现VEGFR1通路的抑制对于调节炎症作用因子至关重要.
结论:
- IAI的MoA涉及VEGFR1和VEGFR2信号通路的同时抑制.
- IAI通过向血管新生,屏障功能和炎症来证明DME的治疗优势.
- 由IAI持续抑制VEGFR1通路可能为DME患者提供显著的好处.
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...